Todas las investigaciones
ReclutamientoExploratorio terapéutico (Fase II)Intervencionista

Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis

This research study is for people who have high blood pressure in their liver, a condition known as portal hypertension, specifically when it's linked to liver scarring (compensated cirrhosis). The main goal is to find out if a new medicine, called BI 685509, can effectively lower this liver pressure. Researchers will compare giving BI 685509 by itself, or in combination with an existing drug called empagliflozin. The study will last 8 weeks. Doctors will measure changes in liver pressure to see which treatment works best. They will also keep an eye on any side effects and whether the treatments prevent complications of liver disease. This is an early-stage study to explore new treatment options.

De un vistazo

Estado
Reclutamiento
Fase
Exploratorio terapéutico (Fase II)
Patrocinador
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim RCV GmbH & Co. KG
Objetivo de inscripción
62
Inicio
24 de mayo de 2023

¿De qué trata este estudio?

This research study is about a condition called portal hypertension. This happens when there's high blood pressure in the main vein that carries blood to your liver (the portal vein). This is often a problem for people who have liver scarring, known as cirrhosis. The study aims to find out if a new medicine can help reduce this high pressure and potentially prevent complications.

The study will look at a new drug, BI 685509. Researchers want to see if this new drug can help lower liver pressure when given on its own, or if it works even better when combined with an existing medicine called empagliflozin. By lowering this pressure, doctors hope to help people with cirrhosis feel better and reduce their risk of severe problems.

Over 8 weeks, participants will receive one of the study treatments. Doctors will carefully measure changes in liver pressure to see how well each treatment works. They will also monitor for any side effects and track whether the treatments help prevent other issues that can arise from advanced liver disease.

Puntos clave

  • Tests new drugs for high blood pressure in the liver (portal hypertension).
  • Aims to lower liver pressure in people with compensated cirrhosis.
  • Compares a new drug (BI 685509) alone or with an existing drug (empagliflozin).
  • Study treatment lasts for 8 weeks.
  • Participation involves regular clinic visits and health checks.
  • Puedes dejar de participar en cualquier momento.

¿Quién puede ser elegible?

To be eligible for this study, you must be 18 years old or older. The study is open to both men and women.

Participants need to have been diagnosed with portal hypertension, which means you have high blood pressure in the main blood vessel leading to your liver. This condition must be linked to compensated cirrhosis, which is a form of liver scarring where your liver is still able to do many of its important jobs.

There will also be other medical checks and criteria that the study doctors will go through with you to make sure the study is a safe and suitable option for your unique health situation.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Do you have high blood pressure in your liver (portal hypertension)?
  3. Is your liver problem related to compensated cirrhosis?
  4. Are you able to attend regular clinic appointments for 8 weeks?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part in this study, you will be given a study medicine to take, either BI 685509 alone or in combination with empagliflozin, for a period of 8 weeks. During this time, you will have regular visits to the clinic so doctors can monitor your health and how the treatment is affecting you.

These visits will involve various assessments, including blood tests and measurements of your liver pressure. These measurements are crucial for the researchers to understand if the treatments are working. Doctors will also check for any side effects you might experience.

After the 8-week treatment period, there will be follow-up appointments to ensure your health remains stable and to collect any final information. The total duration you'd be involved in the study, from your first visit to your last, would be explained to you in detail by the study team.

Riesgos y beneficios potenciales

Taking part in this study may offer potential benefits, such as receiving a new investigational treatment for your portal hypertension that might help lower your liver pressure. However, it's also possible that the treatments may not help, or that you might experience side effects. These could include a drop in blood pressure or fainting, among others. All medical procedures and medications carry some risks, and the study team will explain all known and potential risks to you in detail. Remember, your participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (9)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    España
  • —
    No verificado
    Austria
  • —
    No verificado
    Países Bajos
  • —
    No verificado
    Alemania
  • —
    No verificado
    Dinamarca
  • —
    No verificado
    Francia
  • —
    No verificado
    Italia
  • —
    No verificado
    Bélgica
  • —
    No verificado
    Rumania

Preguntas comunes

What is portal hypertension?

It's when you have high blood pressure in the main vein that carries blood to your liver, often due to liver scarring.

What is compensated cirrhosis?

This is a type of liver scarring where your liver is still working well enough, but it can lead to problems like portal hypertension.

What are BI 685509 and empagliflozin?

BI 685509 is an experimental new drug being tested, and empagliflozin is an existing drug used for other conditions, which is also being explored in this study.

How long will the treatment last?

The active treatment period in this study is 8 weeks.

Will I know which treatment I'm getting?

This is an 'open-label' study, which means you and your doctors will know which treatment you are receiving.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "Randomised, open-label and parallel group trial to investiga…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.